Granules India: US FDA Clears Granules Life Sciences After Shamirpet Facility Inspection

Granules India has announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), has successfully concluded a US FDA inspection with a Voluntary Action Indicated (VAI) classification. The inspection of the manufacturing facility at Shamirpet, Telangana, was conducted between December 15 and 19, 2025, and is now officially closed with no regulatory action recommended.

FDA Inspection Details

The US Food and Drug Administration conducted a comprehensive current Good Manufacturing Practice (cGMP) and pre-approval inspection (PAI) of the oral solid dosage manufacturing operations at the Shamirpet facility. The Establishment Inspection Report (EIR) was subsequently issued, leading to the VAI classification.

Inspection Parameter:	Details
Facility Location:	Shamirpet, Telangana
Inspection Dates:	December 15-19, 2025
Inspection Type:	cGMP and PAI
Classification:	Voluntary Action Indicated (VAI)
Status:	Closed
Regulatory Action:	None recommended

Management Commentary

Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Limited, emphasized the company's commitment to quality standards. "While receiving the classification is a step in the right direction, we recognize that quality is not a one-time milestone but an ongoing commitment. It will continue to remain a core pillar of utmost importance across all Granules sites, guiding our actions, investments, and culture every day," he stated.

Strategic Manufacturing Impact

The VAI classification strengthens Granules India's finished dosage manufacturing capabilities by enabling multi-site manufacturing for approved products. This development allows the company to leverage its manufacturing network more effectively while maintaining regulatory compliance across its facilities.

Regulatory Compliance Significance

A VAI classification from the FDA indicates that while some observations may have been noted during the inspection, they do not warrant immediate regulatory action. This outcome allows GLS to continue its manufacturing operations without major disruptions while maintaining its good standing with the US regulatory authority. The successful completion reinforces the subsidiary's adherence to pharmaceutical manufacturing standards and quality control systems required for the US market.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.31%	-2.46%	+5.38%	+13.07%	+27.11%	+96.73%

Granules India Limited has announced positive regulatory news from its US operations, with the company's subsidiary Granules Consumer Health, LLC receiving a favorable FDA inspection report with No Action Indicated status.

FDA Inspection Results

Granules Consumer Health, LLC, a wholly-owned subsidiary of Granules Pharmaceuticals, Inc., has received an Establishment Inspection Report (EIR) with No Action Indicated (NAI) Status from the US Food and Drug Administration. The FDA inspection was conducted at the company's packaging facility in Manassas, Virginia, from December 1 to 3, 2025.

Inspection Details:	Status
Inspection Period:	December 1-3, 2025
Facility Location:	Manassas, Virginia
FDA Report Status:	No Action Indicated (NAI)
Inspection Round:	Second inspection
Issues Identified:	Zero observations

Facility Operations and Significance

The inspected facility holds significant importance within Granules India's US operations structure. Granules Consumer Health serves as the company's front-end division for OTC products in the US, processing controlled substances and over-the-counter products across three advanced packaging lines. The facility is responsible for packaging both OTC and prescription products and serves as a distribution hub for OTC products across the US market.

Management Commentary

Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, commented on the achievement: "Granules Consumer Health plays a critical role in our global operations as a packaging and distribution site. We process controlled substances and over-the-counter (OTC) products across three advanced packaging lines. Achieving zero observations in this inspection reflects the strong culture of quality, safety and regulatory excellence demonstrated by our teams."

Regulatory Compliance Track Record

This marks the facility's second consecutive FDA inspection with zero observations, following the March 2023 audit which also concluded with no issues identified. The successful completion of the FDA inspection with No Action Indicated status reflects the subsidiary's commitment to maintaining high operational standards and validates the facility's adherence to FDA regulations governing pharmaceutical packaging and distribution operations.